Aveo Oncology announced in late May that the University of Texas M.D. Anderson Cancer Center would lead clinical tests of its promising new cancer drug. What the company's news release did not say is that M.D. Anderson's president is one of its co-founders and owns nearly $8 million worth of its stock.
Hospital's drug trial raises ethical concerns
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.